Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine Patch 1-step Titration in Alzheimer's
NCT02703636Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2016
- Primary completion
- May 2018
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivastigmine in Alzheimer's disease (AD), sponsored by Novartis. Primary endpoint: Mini-Mental State Examination Total Score at 24 weeks. Started May 2016; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02703636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02703636.